On the 15th November 2017, and as a part of the World Antibiotics Awareness Week, EAP has released its statement on Antimicrobial Stewardship (AMS) in collaboration with the European Society for Paediatric Infectious Diseases (ESPID). Underlining the importance of AMS as a key component to tackle Antimicrobial Resistance (AMR), the statement urges all current and upcoming health professionals dealing with child health to ensure a rational prescription of antibiotics to children and young people.
The EAP-ESPID statement followed the entities’ co-authored scientific article “European Antibiotic Awareness Day 2017: training the next generation of health care professionals in antibiotic stewardship”, published in the European Journal of Paediatrics, which takes stock of the benefits of AMS programmes and the ways to make these more accessible, inclusive and comprehensive for all health professionals.
Keeping in line with the #KeepAntiobitcsWorking hashtag coined and promoted by the ECDC, EAP has also released awareness and promotion materials on AMS with EU policy-makers, health professionals and other relevant stakeholders as target audience.
To read the EAP-ESPID statement, please click here.
To access the EAP-ESPID “European Antibiotic Awareness Day 2017: training the next generation of health care professionals in antibiotic stewardship” article, please click here.
To download the EAP-ESPID factsheet on AMS, please click here.
To view the EAP infographic on AMS, please click here.
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.
